Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Suzhou Puhe BioPharma Co., Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit. RAHMANI, NILOOFAR is the busiest examiner, with 1 pending matter. The available prosecution activity is concentrated in a single assignment.
Counsel should focus on the examiner’s treatment of the pharmaceutical or biotechnology claims and identify concrete distinctions supported by the specification. Depending on the objections, useful distinctions may involve composition, biological activity, treatment context, or experimental support, but the response should remain tied to the actual record. No parallel examiner or art-unit assignment is shown. A targeted response or interview can therefore be planned around this matter’s specific claim scope and cited art.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.7% | -2.9% |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729309 | 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | Jul 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Puhe BioPharma Co., Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Niloofar Rahmani has the most, with 1 of Suzhou Puhe BioPharma Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.